NEW YORK--(BUSINESS WIRE)--The Klein Law Firm announces the commencement of an investigation of Acorda Therapeutics, Inc. (NASDAQ: ACOR) concerning possible violations of federal securities laws. On November 15, 2017, Acorda revealed it had ceased enrolling new patients in its Phase 3 trial of its Parkinson’s treatment due to patient deaths.
If you suffered a loss in Acorda and wish to obtain additional information, please contact Joseph Klein, Esq. by telephone at 212-616-4899 or visit http://www.kkclasslaw.com/ACOR-Info-Request-Form-223.
Joseph Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.